42.24
price up icon0.23%   0.095
after-market 시간 외 거래: 42.83 0.585 +1.38%
loading
전일 마감가:
$42.15
열려 있는:
$42.34
하루 거래량:
887.85K
Relative Volume:
0.53
시가총액:
$6.72B
수익:
$705.14M
순이익/손실:
$-453.90M
주가수익비율:
-13.90
EPS:
-3.04
순현금흐름:
$-551.29M
1주 성능:
+1.16%
1개월 성능:
+5.61%
6개월 성능:
+21.57%
1년 성능:
-18.54%
1일 변동 폭
Value
$41.60
$42.55
1주일 범위
Value
$41.25
$42.81
52주 변동 폭
Value
$23.95
$52.34

Ionis Pharmaceuticals Inc Stock (IONS) Company Profile

Name
명칭
Ionis Pharmaceuticals Inc
Name
전화
(760) 931-9200
Name
주소
2855 GAZELLE COURT, CARLSBAD, CA
Name
직원
927
Name
트위터
@ionispharma
Name
다음 수익 날짜
2024-11-06
Name
최신 SEC 제출 서류
Name
IONS's Discussions on Twitter

IONS을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Biotechnology icon
IONS
Ionis Pharmaceuticals Inc
42.24 6.71B 705.14M -453.90M -551.29M -3.04
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
469.65 122.48B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
563.10 60.96B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
328.81 42.77B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
591.99 36.21B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
291.47 31.91B 3.81B -644.79M -669.77M -6.24

Ionis Pharmaceuticals Inc Stock (IONS) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2025-07-01 업그레이드 Barclays Equal Weight → Overweight
2025-04-07 개시 H.C. Wainwright Buy
2025-03-31 개시 Redburn Atlantic Neutral
2024-08-02 다운그레이드 BMO Capital Markets Outperform → Market Perform
2024-07-24 업그레이드 Leerink Partners Market Perform → Outperform
2024-07-16 재개 Jefferies Buy
2024-06-14 업그레이드 Bernstein Underperform → Mkt Perform
2024-04-10 업그레이드 Wolfe Research Peer Perform → Outperform
2024-01-02 업그레이드 BofA Securities Neutral → Buy
2023-10-23 업그레이드 BofA Securities Underperform → Neutral
2023-09-29 개시 Raymond James Strong Buy
2023-07-31 업그레이드 Citigroup Neutral → Buy
2023-06-07 재개 Piper Sandler Overweight
2023-05-04 업그레이드 Citigroup Sell → Neutral
2023-03-21 개시 Bernstein Underperform
2022-12-21 다운그레이드 Morgan Stanley Overweight → Equal-Weight
2022-09-09 재개 Morgan Stanley Overweight
2022-07-18 재개 Oppenheimer Outperform
2022-03-31 재개 Piper Sandler Overweight
2022-03-01 개시 Citigroup Sell
2022-03-01 개시 Guggenheim Buy
2022-02-01 다운그레이드 BofA Securities Buy → Underperform
2021-12-14 업그레이드 William Blair Mkt Perform → Outperform
2021-05-07 업그레이드 UBS Sell → Neutral
2021-03-01 업그레이드 Barclays Underweight → Equal Weight
2020-12-16 개시 UBS Sell
2020-12-15 업그레이드 Cowen Market Perform → Outperform
2020-09-14 재개 JP Morgan Neutral
2020-09-02 개시 The Benchmark Company Hold
2020-06-01 재개 Oppenheimer Outperform
2020-05-13 개시 RBC Capital Mkts Outperform
2020-03-05 개시 Citigroup Buy
2019-12-13 개시 Oppenheimer Outperform
2019-11-13 개시 BofA/Merrill Buy
2019-11-07 다운그레이드 Morgan Stanley Equal-Weight → Underweight
2019-09-10 업그레이드 Bernstein Mkt Perform → Outperform
2018-08-08 재확인 Stifel Hold
2018-08-07 재확인 Stifel Hold
2018-05-08 다운그레이드 Evercore ISI Outperform → In-line
2017-10-06 재개 Goldman Sell
2017-08-17 개시 Evercore ISI Outperform
2017-08-09 재확인 Stifel Hold
2017-03-10 다운그레이드 Goldman Neutral → Sell
2016-12-28 재확인 BMO Capital Markets Outperform
2016-12-27 재확인 Leerink Partners Mkt Perform
모두보기

Ionis Pharmaceuticals Inc 주식(IONS)의 최신 뉴스

pulisher
09:23 AM

KalVista, Biogen, Ionis get EU positive opinions for key drugs (KALV:NASDAQ) - Seeking Alpha

09:23 AM
pulisher
07:55 AM

Is Ionis Pharmaceuticals Inc. a good long term investmentBreakthrough capital growth - Autocar Professional

07:55 AM
pulisher
07:15 AM

TRYNGOLZA Receives EU CHMP Approval Recommendation for Rare Disease FCS Treatment | IONS Stock News - Stock Titan

07:15 AM
pulisher
Jul 23, 2025

Ionis Pharmaceuticals Inc. Stock Analysis and ForecastRemarkably fast returns - jammulinksnews.com

Jul 23, 2025
pulisher
Jul 23, 2025

Ionis Pharmaceuticals (IONS) Earnings Expected to Grow: Should You Buy? - Yahoo Finance

Jul 23, 2025
pulisher
Jul 23, 2025

Ionis Pharmaceuticals founder Stanley Crooke on the fight against rare diseases - MSN

Jul 23, 2025
pulisher
Jul 23, 2025

What analysts say about Ionis Pharmaceuticals Inc. stockRapid portfolio appreciation - Autocar Professional

Jul 23, 2025
pulisher
Jul 23, 2025

What drives Ionis Pharmaceuticals Inc. stock priceHigh-profit trading signals - jammulinksnews.com

Jul 23, 2025
pulisher
Jul 22, 2025

Lou Gehrig’s Disease Clinical, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline Analysis | Ionis Pharmaceuticals, 1ST Biotherapeutics, Scholar Rock, Revalesio, QurAlis Corpo - Barchart.com

Jul 22, 2025
pulisher
Jul 22, 2025

Pinning Down Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS) P/S Is Difficult Right Now - 富途牛牛

Jul 22, 2025
pulisher
Jul 21, 2025

Biogen to Highlight Scientific Progress Across Alzheimer’s Disease at the Alzheimer’s Association International Conference 2025 - GlobeNewswire Inc.

Jul 21, 2025
pulisher
Jul 21, 2025

Friedreich's Ataxia Market Is Expanding Due To Advancing - openPR.com

Jul 21, 2025
pulisher
Jul 21, 2025

Ionis HAE drug shows strong results in switch study - Investing.com Australia

Jul 21, 2025
pulisher
Jul 21, 2025

Phase 3 OASISplus data demonstrating benefit of donidalorsen for HAE patients who switched from other prophylactics published in JACI In Practice - Yahoo Finance

Jul 21, 2025
pulisher
Jul 17, 2025

Global Motor Neuron Disease Treatment Market to Exhibit Substantial Growth at a CAGR of ~6% by 2032 | DelveInsight - Yahoo Finance

Jul 17, 2025
pulisher
Jul 17, 2025

Hutchinson-Gilford Progeria Syndrome Market Driven - openPR.com

Jul 17, 2025
pulisher
Jul 16, 2025

(IONS) Technical Data - news.stocktradersdaily.com

Jul 16, 2025
pulisher
Jul 16, 2025

Ionis Pharmaceuticals to Host Q2 2025 Earnings Webcast on July 30th - AInvest

Jul 16, 2025
pulisher
Jul 16, 2025

Ionis to hold second quarter 2025 financial results webcast - Business Wire

Jul 16, 2025
pulisher
Jul 16, 2025

Ionis To Hold Second Quarter 2025 Financial Results Webcast - Barchart.com

Jul 16, 2025
pulisher
Jul 15, 2025

Ionis Pharma CEO Monia sells $48,416 in stock By Investing.com - Investing.com Canada

Jul 15, 2025
pulisher
Jul 15, 2025

Ionis Pharmaceuticals CEO Monia Brett Sells 1160 Shares at $41.74 - AInvest

Jul 15, 2025
pulisher
Jul 14, 2025

Multiple System Atrophy Clinical Trials 2025: EMA, PDMA, FDA Approvals, Medication, Therapies, Treatment Market, Mechanism of Action, Route of Administration, and Companies by DelveInsight - The Globe and Mail

Jul 14, 2025
pulisher
Jul 14, 2025

Spinocerebellar Ataxias Pipeline 2025: MOA, ROA, and Clinical Trial Insights Explored by DelveInsight | Biogen Inc, BioXcel Corp, Celavie Biosciences, Ionis Pharma, Anima Biotech Inc, Biohaven Pharma - Barchart.com

Jul 14, 2025
pulisher
Jul 10, 2025

Barclays Upgrades Ionis Pharmaceuticals (IONS) Stock, Raises PT - Insider Monkey

Jul 10, 2025
pulisher
Jul 09, 2025

11 Best Mid-cap Healthcare Stocks to Buy According to Hedge Funds - Insider Monkey

Jul 09, 2025
pulisher
Jul 06, 2025

Ionis Pharmaceuticals’ SWOT analysis: stock outlook amid pipeline progress - Investing.com

Jul 06, 2025
pulisher
Jul 06, 2025

Ionis (IONS) Announces Leadership Transition as R&D Veteran Richard Geary Prepares to Retire - MSN

Jul 06, 2025
pulisher
Jul 04, 2025

Ionis Pharmaceuticals (IONS) Moves 9.1% Higher: Will This Strength Last? - MSN

Jul 04, 2025
pulisher
Jul 04, 2025

Ionis' Tryngolza Cuts Triglyceride Levels in Late-Stage Study - MSN

Jul 04, 2025
pulisher
Jul 03, 2025

Should You Buy Ionis Pharmaceuticals (IONS) After Golden Cross? - Zacks Investment Research

Jul 03, 2025
pulisher
Jul 03, 2025

Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS) Shares Climb 28% But Its Business Is Yet to Catch Up - simplywall.st

Jul 03, 2025
pulisher
Jul 02, 2025

Ionis Pharmaceuticals Surges Amid Promising SMA Treatment Progress - StocksToTrade

Jul 02, 2025
pulisher
Jul 02, 2025

Ionis Pharmaceuticals Advances as Barclays Upgrades Stock - timothysykes.com

Jul 02, 2025
pulisher
Jul 02, 2025

Ionis Pharmaceuticals shares surge 8.89% intraday after Barclays analyst upgrades rating to 'Overweight'. - AInvest

Jul 02, 2025
pulisher
Jul 01, 2025

10 Analysts Assess Ionis Pharmaceuticals: What You Need To Know - Nasdaq

Jul 01, 2025

Ionis Pharmaceuticals Inc (IONS) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading

Ionis Pharmaceuticals Inc 주식 (IONS) 내부자 거래

내부자 거래 관계 날짜 거래 비용 #주식 가치 ($) #주식 총계
YANG MICHAEL J.
Director
Jul 15 '25
Option Exercise
0.00
4,079
0
6,010
WENDER JOSEPH H
Director
Jul 15 '25
Option Exercise
0.00
4,079
0
136,835
PARSHALL B LYNNE
Director
Jul 15 '25
Option Exercise
0.00
4,079
0
91,344
HERMAN JOAN E
Director
Jul 15 '25
Option Exercise
0.00
4,079
0
46,086
Hayden Michael R
Director
Jul 15 '25
Option Exercise
0.00
4,079
0
54,298
Diaz Allene M.
Director
Jul 15 '25
Option Exercise
0.00
4,079
0
19,795
BERTHELSEN SPENCER R
Director
Jul 15 '25
Option Exercise
0.00
4,079
0
156,013
Monia Brett P
Chief Executive Officer
Jul 11 '25
Sale
41.74
1,160
48,416
179,820
Hayden Michael R
Director
May 01 '25
Buy
31.86
15,000
477,900
50,219
Birchler Brian
EVP, Corp and Development Ops
Apr 15 '25
Option Exercise
0.00
1,875
0
57,340
$23.40
price down icon 0.97%
$36.67
price up icon 0.22%
$103.95
price up icon 0.42%
$28.67
price up icon 3.99%
$115.31
price up icon 0.65%
biotechnology ONC
$291.47
price down icon 1.68%
자본화:     |  볼륨(24시간):